Work

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps5090

Authors: Rahul Raj Aggarwal, Scott E. Eggener, Ronald C. Chen, Glenn Heller, Akash Patnaik, Han Xiao, Douglas Weckstein, James Mohler, Mark Watson, Mary-Ellen Taplin, Linda A. Skoog-Sluman, Meryl Pereji, Eunice Aikins-Afful, J Kellogg Parsons, Charles J. Ryan, Michael J. Morris

Institutions: University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of Chicago, University of North Carolina at Chapel Hill, Memorial Sloan Kettering Cancer Center, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Roswell Park Comprehensive Cancer Center, Washington University in St. Louis, Alliance Foundation Trials, University of California San Diego, Moores Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890996975

Cites:

Cited by: 5

Related to: 10